| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
339.06(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,166 |
| 52
Week Range: |
$0.8406 - $6.3 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 5 |
| Insider 3/6 Months : 5.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
6,000 |
45,969 |
69,569 |
| Total Buy Value |
$0 |
$17,420 |
$52,303 |
$115,200 |
| Total People Bought |
0 |
2 |
4 |
5 |
| Total Buy Transactions |
0 |
2 |
6 |
20 |
| Total Shares Sold |
672,392 |
672,392 |
782,046 |
807,046 |
| Total Sell Value |
$3,828,036 |
$3,828,036 |
$3,925,182 |
$4,001,682 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
20 |
20 |
23 |
25 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Czirr James C |
10% Owner |
– – • |
2025-12-03 |
4/A |
S |
$5.73 |
$756,755 |
D/D |
(132,069) |
5,670,138 |
|
- |
|
| Czirr James C |
10% Owner |
– – • |
2025-12-03 |
4 |
S |
$5.73 |
$687,600 |
D/D |
(120,000) |
5,682,207 |
|
-1% |
|
| Czirr James C |
10% Owner |
– – • |
2025-12-02 |
4 |
S |
$5.47 |
$164,100 |
D/D |
(30,000) |
5,802,207 |
|
-5% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-18 |
4 |
AS |
$6.15 |
$41,723 |
D/D |
(6,783) |
832,592 |
|
-7% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-18 |
4 |
OE |
$2.39 |
$16,211 |
D/D |
6,783 |
839,375 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-18 |
4 |
AS |
$6.22 |
$288,187 |
D/D |
(46,310) |
7,614 |
|
-7% |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-18 |
4 |
OE |
$1.11 |
$75,851 |
D/D |
46,310 |
25,824 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-17 |
4 |
AS |
$6.04 |
$94,643 |
D/D |
(15,680) |
832,592 |
|
-4% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-17 |
4 |
OE |
$2.39 |
$37,475 |
D/D |
15,680 |
848,272 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-17 |
4 |
AS |
$6.03 |
$190,662 |
D/D |
(31,610) |
7,614 |
|
-4% |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-17 |
4 |
OE |
$1.11 |
$43,706 |
D/D |
31,610 |
9,937 |
|
- |
|
| Jamil Khurram |
Chief Medical Officer |
• – – |
2025-11-13 |
4 |
AS |
$5.47 |
$662,510 |
D/D |
(121,117) |
4,479 |
|
4% |
|
| Jamil Khurram |
Chief Medical Officer |
• – – |
2025-11-13 |
4 |
OE |
$1.23 |
$215,038 |
D/D |
99,250 |
20,729 |
|
- |
|
| Czirr James C |
10% Owner |
– – • |
2025-11-11 |
4 |
S |
$5.25 |
$210,000 |
D/D |
(40,000) |
5,832,207 |
|
-4% |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-10 |
4 |
AS |
$6.02 |
$31,884 |
D/D |
(5,291) |
7,614 |
|
10% |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-10 |
4 |
OE |
$1.11 |
$7,717 |
D/D |
5,291 |
9,350 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-10 |
4 |
AS |
$6.03 |
$11,252 |
D/D |
(1,867) |
832,592 |
|
10% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-10 |
4 |
OE |
$2.39 |
$4,462 |
D/D |
1,867 |
834,459 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-05 |
4 |
AS |
$6.00 |
$3,600 |
D/D |
(600) |
7,614 |
|
2% |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-05 |
4 |
OE |
$1.11 |
$962 |
D/D |
600 |
7,814 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-05 |
4 |
AS |
$6.00 |
$1,200 |
D/D |
(200) |
832,592 |
|
2% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-05 |
4 |
OE |
$2.39 |
$478 |
D/D |
200 |
832,792 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-04 |
4 |
AS |
$6.07 |
$87,529 |
D/D |
(14,420) |
832,592 |
|
1% |
|
| Lewis Joel |
President and CEO |
• • – |
2025-11-04 |
4 |
OE |
$2.39 |
$34,464 |
D/D |
14,420 |
847,012 |
|
- |
|
| Callicutt Jack W |
Chief Financial Officer |
• – – |
2025-11-04 |
4 |
AS |
$6.07 |
$173,778 |
D/D |
(28,629) |
7,614 |
|
1% |
|
347 Records found
|
|
Page 1 of 14 |
|
|
0.08 (1.33%) 
